NCT05222971View on ClinicalTrials.gov

Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Biliary Tract CancerDNA Damage Repair Deficiency
Interventions
DRUG

Durvalumab

"Durvalumab 1,500 mg IV on Day 1~Every 4 weeks"

DRUG

Olaparib

"Olaparib 300 mg twice daily~Every 4 weeks"

Trial Locations (1)

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT05222971 - Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy | Biotech Hunter | Biotech Hunter